Dr. Ginsburg on Determining Genetic Testing in Gynecologic Malignancies
Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.
Women in families with MSH2 germline mutation for Lynch syndrome need to be counseled, especially if they test positive for the mutation, states Ginsburg. These women have a very high risk of uterine cancer and endometrial cancer. Additionally, the risk of uterine cancer in those families is higher than the risk of ovarian cancer.
Related Videos
Related Content
